(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.31%) $0.929
(-1.07%) $10.87
(-0.13%) $0.797
(0.35%) $91.45
1.64% HKD 0.620
Live Chart Being Loaded With Signals
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide...
Stats | |
---|---|
Объем за сегодня | 1.27M |
Средний объем | 5.07M |
Рыночная капитализация | 1.33B |
EPS | HKD0 ( 2023-08-29 ) |
Дата следующего отчета о доходах | ( HKD0 ) 2024-06-26 |
Last Dividend | HKD0.0100 ( 2021-06-16 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.13 |
ATR14 | HKD0.00200 (0.33%) |
Объем Корреляция
VIVA Biotech Holdings Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
VIVA Biotech Holdings Корреляция - Валюта/Сырье
VIVA Biotech Holdings Финансовые показатели
Annual | 2023 |
Выручка: | HKD2.16B |
Валовая прибыль: | HKD738.43M (34.26 %) |
EPS: | HKD-0.0598 |
FY | 2023 |
Выручка: | HKD2.16B |
Валовая прибыль: | HKD738.43M (34.26 %) |
EPS: | HKD-0.0598 |
FY | 2022 |
Выручка: | HKD2.38B |
Валовая прибыль: | HKD815.68M (34.28 %) |
EPS: | HKD-0.280 |
FY | 2021 |
Выручка: | HKD2.10B |
Валовая прибыль: | HKD650.98M (30.94 %) |
EPS: | HKD0.150 |
Financial Reports:
No articles found.
VIVA Biotech Holdings Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.00500 | 2019-09-09 |
Last Dividend | HKD0.0100 | 2021-06-16 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | HKD0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.9 | -- |
Div. Sustainability Score | 7.09 | |
Div.Growth Potential Score | 1.996 | |
Div. Directional Score | 4.54 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6806.HK | Ex Dividend Junior | 2023-06-26 | Annually | 0 | 0.00% | |
1905.HK | Ex Dividend Knight | 2023-10-20 | Semi-Annually | 0 | 0.00% | |
0934.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2886.HK | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
1501.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% | |
8095.HK | Ex Dividend Junior | 2023-10-17 | Sporadic | 0 | 0.00% | |
2005.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
1075.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0539 | 1.500 | -1.077 | -1.616 | [0 - 0.5] |
returnOnAssetsTTM | -0.0156 | 1.200 | -0.520 | -0.623 | [0 - 0.3] |
returnOnEquityTTM | -0.0317 | 1.500 | -1.463 | -2.19 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.324 | 0.800 | 8.38 | 6.70 | [1 - 3] |
quickRatioTTM | 0.941 | 0.800 | 9.17 | 7.34 | [0.8 - 2.5] |
cashRatioTTM | 0.675 | 1.500 | 7.36 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.255 | -1.500 | 5.74 | -8.61 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.447 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.228 | 2.00 | 9.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.516 | -1.500 | 7.94 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.343 | 1.000 | 7.62 | 7.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0894 | 1.000 | -0.212 | -0.212 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.201 | 1.000 | 9.99 | 9.99 | [0.2 - 2] |
assetTurnoverTTM | 0.289 | 0.800 | -1.404 | -1.124 | [0.5 - 2] |
Total Score | 7.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -4.24 | 1.000 | -0.529 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0317 | 2.50 | -0.941 | -2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.228 | 2.00 | 9.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.447 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0216 | 1.500 | -3.48 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.178 | 1.000 | 8.05 | 0 | [0.1 - 0.5] |
Total Score | 1.996 |
VIVA Biotech Holdings
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа